Zydus Cadila has received the final approval from the USFDA to market Amantadine Hydrochloride Capsules USP, 100 mg. The estimated sale for Amantadine Hydrochloride Capsules USP as per IMS (MAT April 2016) is $ 40.1 million. The drug which is used in the treatment of Parkinson's disease and select viral infections will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
